Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure

Basic Details
Date Posted
Tuesday, August 25, 2020
Status
Complete
Medical Product
angiotensin II receptor blocker (ARB)
angiotensin-converting enzyme (ACE) inhibitor
sacubitril/valsartan
Description

In this analysis we examined counts of new users of sacubitril/valsartan, angiotensin-converting enzyme (ACE) inhibitors, and other angiotensin II receptor blockers (ARBs) with heart failure in the Sentinel Distributed Database (SDD). We also captured switching between products.

This analysis include two reports containing data from 16 Data Partners contributing to the SDD. Data from January 1, 2015 to July 31, 2019 were included in Report 1, which was distributed on December 6, 2019. Data from January 1, 2015 to July 31, 2019 were included in Report 2, which was distributed on February 27, 2020.

Additional Details
FDA Center
CDER
Time Period
January 1, 2015 - July 31, 2019
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Individuals 18 years of age and older
Data Sources
Sentinel Distributed Database (SDD)